公开(公告)号：WO2008064317A1

公开(公告)日：2008-05-29

申请号：PCT/US2007/085394

申请日：2007-11-21

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  WELSH, William, J. ,  ARORA, Sonia ,  YANG, Kaipeen

Inventor： WELSH, William, J. ,  ARORA, Sonia ,  YANG, Kaipeen

IPC: A01N57/00 ,  A61K31/675

CPC classification number: C07D249/08

Abstract: Substituted pyrazoles, imidazoles, triazoles, other 5-membered heteroaromatic ring compounds, substituted 6-membered heteroaromatic ring compounds, and fluorene and carbazole compounds, may be included in pharmaceutical central nervous system drug compositions to treat a condition mediated by an opioid receptor in a patient. Such compounds are designed to possess improved transport across the blood-brain barrier. These compounds possess an optimal combination of high lipophilicity, low polarity, limited conformational flexibility, and few hydrogen bonding groups. Such lipophilic opioid receptor active compounds are useful for treating pain, inflammation, arthritis, central nervous system disorders, and other diseases.

Abstract translation: 取代的吡唑，咪唑，三唑，其它5元杂芳环化合物，取代的6元杂芳环化合物，以及芴和咔唑化合物可以包括在药物中枢神经系统药物组合物中，以治疗由阿片受体介导的病症 患者。 这些化合物被设计成具有穿过血脑屏障的改善的运输。 这些化合物具有高亲油性，低极性，有限的构象柔性和少量氢键基团的最佳组合。 这样的亲脂性阿片受体活性化合物可用于治疗疼痛，炎症，关节炎，中枢神经系统疾病和其他疾病。

公开(公告)号：WO2008024919A2

公开(公告)日：2008-02-28

申请号：PCT/US2007/076655

申请日：2007-08-23

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  KOTENKO, Sergei, V. ,  SMITH, Geoffrey, L.

Inventor： KOTENKO, Sergei, V. ,  SMITH, Geoffrey, L.

IPC: A61K38/21 ,  A61K39/395

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K38/162 ,  C07K16/081 ,  C12N7/00 ,  C12N2710/24033 ,  C12N2710/24122

Abstract: [00243] Described are compositions and methods useful for modulating the immune system of a subject. Also included are diagnostic methods for monitoring an immunologic condition. In particular the invention relates to antagonists of interferon proteins and associated methods of use as well as methods to develop neutralizing antibodies against IFN antagonists to treat viral infections.

Abstract translation: 描述了用于调节受试者免疫系统的组合物和方法。 还包括监测免疫状况的诊断方法。 具体地说，本发明涉及干扰素蛋白的拮抗剂和相关的使用方法以及开发针对IFN拮抗剂的中和抗体以治疗病毒感染的方法。

公开(公告)号：WO2007109781A2

公开(公告)日：2007-09-27

申请号：PCT/US2007/064739

申请日：2007-03-22

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  INOUYE, Masayori ,  WOYCHIK, Nancy ,  INOUE, Koichi

Inventor： INOUYE, Masayori ,  WOYCHIK, Nancy ,  INOUE, Koichi

IPC: C12Q1/68

CPC classification number: C12Q1/6818

Abstract: The invention provides methods for identifying an agent which prevents or partially prevents an antitoxin from forming a complex with its cognate toxin, comprising contacting a potential agent with a labeled substrate in solution, whereby detection of the label indicates presence of an agent that prevents an antitoxin from forming complex with a toxin. The invention also provides agents capable of interfering with formation of a toxin-antitoxin complex. Such agents act as novel, non-conventional antibiotics against human pathogenic bacteria.

Abstract translation: 本发明提供用于鉴定防止或部分防止抗毒素与其同源毒素形成复合物的试剂的方法，包括使潜在试剂与溶液中的标记底物接触，由此检测标记表示存在防止抗毒素的试剂 从形成复杂的毒素。 本发明还提供能够干扰毒素 - 抗毒素复合物形成的试剂。 这些试剂作为抗人类病原菌的新型非常规抗生素。

公开(公告)号：WO2007062150A3

公开(公告)日：2007-05-31

申请号：PCT/US2006/045258

申请日：2006-11-22

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  KACHLANY, Charles, S.

Inventor： KACHLANY, Charles, S.

IPC: C07K14/285 ,  A61P35/02 ,  C07K1/113

Abstract: A composition comprising leukotoxin proteins isolated from a bacterium is provided. In this composition, greater than 85% of the leukotoxin proteins are chemically modified at a basic amino acid residue, and the proteins induce cell death in myeloid leukocytes, while remaining substantially non-toxic to lymphoid leukocytes, lymphocytes, and red blood cells. Also provided is a method of selectively inducing cell death in myeloid leukocytes. The method comprises contacting the myeloid leukocytes with a composition comprising leukotoxin proteins. These leukotoxin proteins may be isolated from the NJ4500 strain of Actinobacillus actinomycetemcomitans. A method of purifying leukotoxin protein from the NJ4500 strain of Actinobacillus actinomycetemcomitans is also provided.

公开(公告)号：WO2006039621A2

公开(公告)日：2006-04-13

申请号：PCT/US2005/035418

申请日：2005-10-03

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  DOROVKOV, Maxim, V. ,  RYAZANOV, Alexey, G. ,  RYAZANOVA, Lillia, V.

Inventor： DOROVKOV, Maxim, V. ,  RYAZANOV, Alexey, G. ,  RYAZANOVA, Lillia, V.

IPC: C07K14/705

CPC classification number: C07K14/705 ,  A61K38/45

Abstract: Methods of inhibiting annexin 1 induced apoptosis by contacting a cell population containing a TRPM7/ChaK1 kinase with an effective amount of a composition containing an inhibitor for the kinase.

Abstract translation: 通过使含有TRPM7 / ChaK1激酶的细胞群与有效量的含有激酶抑制剂的组合物接触来抑制膜联蛋白1诱导的细胞凋亡的方法。

公开(公告)号：WO2004061117A3

公开(公告)日：2004-07-22

申请号：PCT/US2003/034683

申请日：2003-10-31

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  KAPLAN, Jeffrey, B.

Inventor： KAPLAN, Jeffrey, B.

IPC: C12N1/21

Abstract: Isolated nucleic acid sequences and amino acid sequences for soluble, β-N-acetylglucosaminidase or active fragments or variants thereof which promote detachment of bacterial cells from a biofilm are provided. An isolated mutant bacteria which forms biofilm colonies which tightly adhere to surface but which are unable to release cells into the medium or spread over the surface is also provided. In additions, methods are described for modulating detachment of bacterial cells from biofilm by mutating soluble,β-N-acetylglucosaminidase or altering its expression or activity are also provided. Also provided are compositions, methods and devices for preventing, inhibiting and treating bacterial infections.

公开(公告)号：WO2004041778A3

公开(公告)日：2004-05-21

申请号：PCT/US2003/034777

申请日：2003-10-31

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  BLACK, Ira, B.

Inventor： BLACK, Ira, B.

IPC: A61K38/18 ,  C12Q1/68

Abstract: The present invention relates to a method of modulating synaptic growth or plasticity by increasing the expression of genes found to be induced by BNDF. Such genes include c-fos proto-oncogene, early growth response protein 1, activity-regulated cytoskeletal associated, fos-related antigen 2, G1/S-specific cyclin D1, voltage­gated potassium channel protein, sodium channel beta 1 subunit, secretogranin II precursor, somatostatin receptor 4, transmembrane receptor UNC5 homology, neuropeptide Y, VGF protein precursor and protein-tyrosine phosphatase 1B. Methods of identifying agents which modulate the expression of these genes and the use of such agents for treating a disease or condition associated with damaged or diseased synapses are also provided.

公开(公告)号：WO2003072709A3

公开(公告)日：2003-09-04

申请号：PCT/US2003/005041

申请日：2003-02-21

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  MATHEWS, Michael, B. ,  PE'ERY, Tsafi ,  REZA, Syed

Inventor： MATHEWS, Michael, B. ,  PE'ERY, Tsafi ,  REZA, Syed

IPC: A61K38/00

Abstract: Variants of the HIV-1 Tat protein exhibiting higher transcriptional activation and stronger P-TEFb binding than wild-type Tat are provided. In addition variants that can inhibit transcription activation by wild-type Tat are provided. Nucleic acid sequences encoding these variants, vectors and host cells for expression of these variants, and antibodies raised against these variants are also provided. In addition, methods for use of these variants and compositions containing these variants as research tools, as diagnostic tools and in the treatment of viral infections are provided.

公开(公告)号：WO2003066092A1

公开(公告)日：2003-08-14

申请号：PCT/US2003/003596

申请日：2003-02-07

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  TRAN, Jean-Luc, V. ,  HEWITT, Charles, W. ,  DOOLIN, Edward, J.

Inventor： TRAN, Jean-Luc, V. ,  HEWITT, Charles, W. ,  DOOLIN, Edward, J.

IPC: A61K39/00

CPC classification number: C07K14/47 ,  A61K39/385 ,  A61K2039/6043

Abstract: The present invention relates to a method of manufacturing and using heat shock proteins containing a step of initiating a coagulative necrotic process in a tissue. In particular, a method of manufacturing and using heat shock proteins comprises the steps of heating a tissue to initiate the coagulative necrotic process for a period of time, cooling the tissue, incubating the tissue in an appropriate growth medium, and collecting the supernatant from the tissue. In a preferred embodiment, the coagulative necrotic process is initiated by heating the tissue to 60°; or more. The tissue is then cooled to room temperature before incubating the tissue in growth media for 48 hours or less. Heat shock proteins produced in accordance with this method may be complexed to peptides or antigens to produce autologous vaccines in the prevention and treatment of various diseases. Furthermore, heat shock proteins may be used in diagnostic assays for various autoimmune and inflammatory diseases. Heat shock proteins produced in accordance with this method may also be used to quantify antibody levels that serve as disease markers.

Abstract translation: 本发明涉及制备和使用热休克蛋白的方法，所述热休克蛋白包含在组织中引发凝固性坏死过程的步骤。 特别地，制造和使用热休克蛋白的方法包括以下步骤：加热组织以引发凝固性坏死过程一段时间，冷却组织，将组织孵育在合适的生长培养基中，并从 组织。 在优选的实施方案中，通过将组织加热至60°来启动凝固性坏死过程; 或者更多。 然后将组织冷却至室温，然后将组织在生长培养基中孵育48小时或更短。 根据该方法产生的热休克蛋白可能与肽或抗原复合以产生自体疫苗以预防和治疗各种疾病。 此外，热休克蛋白可用于各种自身免疫性和炎性疾病的诊断测定。 根据该方法产生的热休克蛋白也可用于定量用作疾病标记物的抗体水平。

公开(公告)号：WO2003016514A1

公开(公告)日：2003-02-27

申请号：PCT/US2002/026605

申请日：2002-08-20

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

Inventor： SEIFER, David, B. ,  MACLAUGHLIN, David, T.

IPC: C12N5/06

CPC classification number: A61K38/22 ,  G01N33/689 ,  G01N2800/36 ,  G01N2800/367 ,  G01N2800/52

Abstract: Methods and kits are provided for assessing the ovarian reserve and predicting the ovarian response to fertility treatments in a female subject. The serum levels of MIS are shown to be positively correlated with the production and retrieval of mature oocytes and serve as prognostic indicators for the female reponse to fertility treatment. The MIS levels can be monitored prior to and during fertility treatment and are useful to adjust the timing and dosage of treatments in order to produce optimal outcome in individual patients, to avoid ovarian hyperstimulation, or to indicate cancellation of an unsuccessful treatment. MIS can also be administered to women to stimulate follicle development and to prevent depletion of ovarian reserve.

Abstract translation: 提供方法和试剂盒用于评估卵巢储备和预测卵巢对女性受试者的生殖治疗反应。 MIS的血清水平显示与成熟卵母细胞的产生和恢复正相关，并且作为对生育治疗的女性反应的预后指标。 可以在生殖治疗之前和期间监测MIS水平，并且有助于调整治疗的时间和剂量，以便在个体患者中产生最佳结果，以避免卵巢过度刺激，或指示取消不成功的治疗。 也可以向妇女施用管理信息系统以刺激卵泡发育并防止卵巢储备的消耗。